New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
10:56 EDTMDXGMiMedx says EpiFix addded as covered product in Jurisdiction H
MiMedx Group announced that the Medicare Administrative Contractor responsible for Jurisdiction H, which has approximately five million beneficiaries in Texas, Oklahoma, Louisiana, New Mexico, Colorado, Mississippi and Arkansas, has revised its Local Coverage Determination, LCD, for bioengineered skin substitutes in the hospital outpatient and physician office settings to include EpiFix. The revision to the LCD, entitled Bioengineered Skin Substitutes, names MiMedx's wound care allograft, EpiFix, as eligible for Medicare coverage when medically necessary and reasonable, subject to the coverage indications and limitations set forth in the LCD. The revision was published on July 10, effective for dates of service on or after June 16. Parker H. "Pete" Petit, Chairman and CEO, said, "As we discussed in our shareholder call on April 25, the contractor for Jurisdiction H previously had issued a draft consolidated LCD under which all skin substitutes with a Q-code were eligible for coverage if the case met the medically necessary and reasonable threshold. This LCD was to go into effect on March 27. On the effective date, the draft LCD was rescinded, and the contractor reverted to the previous LCD. The previous Jurisdiction H LCD covered only a few named skin substitutes and did not include coverage for EpiFix. In the update issued on July 10, the contractor has added EpiFix as a covered product. EpiFix was the only product added in that update. We are very pleased that EpiFix has been included in the revised LCD for this Medicare jurisdiction."
News For MDXG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2015
07:06 EDTMDXGMiMedx Q2 results solid, says Brean Capital
Subscribe for More Information
July 30, 2015
07:45 EDTMDXGMiMedx backs FY15 revenue view $180M-$190M, consensus $187.44M
Sees FY15 operating margin 12%-14%.
07:44 EDTMDXGMiMedx sees Q3 revenue $47M-$50M, consensus $48.68M
Sees Q3 operating profit 13%-15%.
07:43 EDTMDXGMiMedx reports Q2 EPS 5c, consensus 5c
Reports Q2 revenue $45.7M, consensus $44.99M.
July 29, 2015
10:00 EDTMDXGOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:28 EDTMDXGMiMedx downgraded to Buy from Strong Buy at Needham
Needham downgraded MiMedx to Buy from Strong Buy with a $15 price target. The firm said MiMedx faces more difficult comps the rest of the year and downgraded shares based on limited upside to consensus estimates and valuation.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use